July 28, 2022
Novocure Reports Second Quarter 2022 Financial Results
Quarterly net revenues of $140.9 million, a 6% increase year-over-year ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and… Read More
learn more
July 27, 2022
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Awards aim to promote and support innovative research on Tumor Treating Fields to deepen understanding and accelerate the development of new treatment strategies ROOT, Switzerland–(BUSINESS WIRE)–Novocure today announced the recipients of the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The AACR-Novocure Grants for Tumor Treating… Read More
learn more
July 1, 2022
Novocure to Report Second Quarter 2022 Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2022 on Thursday, July 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss the company’s financial results for the three and… Read More
learn more
